Clinical Trial Detail

NCT ID NCT01415752
Title Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eastern Cooperative Oncology Group
Indications

mantle cell lymphoma

Therapies

Bortezomib

Bendamustine

Rituximab

Lenalidomide

Age Groups: senior adult

No variant requirements are available.